Halfon P
-
Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.
-
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
-
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
-
ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.
-
Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.
-
Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C.
-
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
-
GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics.
-
Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.
-
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
-
Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.
-
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C.
-
Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication
-
Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.
-
Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.
-
External validation of FibroIndex.
-
Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
-
Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.
-
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
-
Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.
-
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication
-
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
-
Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
-
Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.
-
Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?
-
Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
-
Analytical variability of the Fibrotest proteins.
-
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.